North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
|Articles|August 1, 1998
The American Journal of Managed Care
- August 1998
- Volume 4
- Issue 8
Generic Drug Product Equivalence: Current Status
Author(s)Marvin C. Meyer, PhD
Advertisement
Articles in this issue
about 28 years ago
Identification and Assessment of High-Risk Seniorsabout 28 years ago
Outpatient Antidepressant Utilization in a Dutch Sick Fundabout 28 years ago
Inborn Errors of Metabolism: Medical and Administrative "Orphans"Advertisement
Related to this article
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
A follicular lymphoma survivor shares axi-cel CAR T-cell therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improve quality of life.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Advertisement
Advertisement